GT
IOVA icon

Glenmede Trust’s Iovance Biotherapeutics IOVA Stock Holding History

Glenmede Trust’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25,233
Closed -$374K – 1386
2024
Q1 		$374K Buy
+25,233
New +$294K ﹤0.01% 1004
2021
Q1 		– Sell
-15,009
Closed -$696K – 1224
2020
Q4 		$696K Buy
15,009
+5,571
+59% +$221K ﹤0.01% 759
2020
Q3 		$310K Buy
9,438
+2,008
+27% +$61.6K ﹤0.01% 908
2020
Q2 		$203K Buy
7,430
+400
+6% +$13.2K ﹤0.01% 1007
2020
Q1 		$194K Hold
7,030
– – ﹤0.01% 1203
2019
Q4 		$194K Buy
7,030
+325
+5% +$7.39K ﹤0.01% 1203
2019
Q3 		$122K Buy
6,705
+135
+2% +$2.98K ﹤0.01% 1336
2019
Q2 		$161K Buy
+6,570
New +$99K ﹤0.01% 1239

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Glenmede Trust's IOVA Position: Q2 2024 in Review

Glenmede Trust sold out of Iovance Biotherapeutics (IOVA) in Q2 2024, closing a stake of 25,233 shares — an estimated $374K sold.

Glenmede Trust first reported a position in IOVA in Q2 2019 and held it in 8 quarters. The position peaked at $696K in Q4 2020. 295 funds tracked by Wall St. Rank hold IOVA as of Q2 2024.

  • Glenmede Trust reported no remaining Iovance Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Glenmede Trust sold 25,233 Iovance Biotherapeutics shares in Q2 2024, an estimated $374K.
  • Glenmede Trust first reported a position in Iovance Biotherapeutics in Q2 2019 and held it in 8 quarters.
  • Glenmede Trust's Iovance Biotherapeutics position peaked at $696K in Q4 2020.
  • 295 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2024.

Based on Glenmede Trust's 13F filing for Q2 2024, filed 14 Aug 2024.